EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort

Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte rat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Prelaj, Arsela, Ferrara, Roberto, Rebuzzi, Sara Elena, Proto, Claudia, Signorelli, Diego, Galli, Giulia, De Toma, Alessandro, Randon, Giovanni, Pagani, Filippo, Viscardi, Giuseppe, Brambilla, Marta, Trevisan, Benedetta, Ganzinelli, Monica, Martinetti, Antonia, Gallucci, Rosaria, Di Mauro, Rosa Maria, Molino, Giuliano, Zilembo, Nicoletta, Torri, Valter, de Braud, Filippo Maria, Garassino, Marina Chiara, Lo Russo, Giuseppe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6966664/
https://ncbi.nlm.nih.gov/pubmed/31817541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11121954
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller